GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of France: pharmacology, and what it actually costs here — 25 comments in the full submission. View in context.
2.1k
c/glp1science·submitted 1 months ago by u/elodie_grimaldi

France: pharmacology, and what it actually costs here

Explainerbranch of 8 comments

Something I noticed reading old threads that I have not seen said out loud. The advice on half-life in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with…

Read the full submission and all 25 comments →

This branch

8 comments, started 1 months ago
u/camila_mensa155 points·1 months ago

glucagon-receptor contribution is appetite for dual and triple agonism

replysharereportpermalink
u/tomas_broberg73 points·1 months ago

This is correct. Rodent data is investigational, not predictive.

replysharereportpermalink
[removed]55 points·1 months ago

[removed by moderator]

replysharereportpermalink
u/aleksi_eriksen0 points·1 months ago

the 12-day half-life means week 12 is still ramp-up pharmacokinetically

replysharereportpermalink
u/kian_balogun37 points·1 months ago

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

replysharereportpermalink
u/neha_krastev54 points·1 months ago

amylin is not GLP-1, posts conflating them get corrected

replysharereportpermalink
u/camila_kowalski197 points·1 months ago

the half-life is receptor, affects steady state timing

replysharereportpermalink
u/emeka_chowdhury103 points·1 months ago

receptor distribution matters, GLP-1 is not everywhere

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.